ABSTRACT
BACKGROUND: Drug users reportedly abuse pregabalin, and its combination with opiates was related to fatalities. We aimed to estimate the prevalence of pregabalin misuse and risk factors among patients in methadone maintenance treatment (MMT). METHODS: A cross-sectional study included all current MMT patients (nâ¯=â¯300) after excluding 9 with prescriptions, from a large tertiary medical center university-affiliated MMT clinic in Israel. Pregabalin was tested in one of the routine urine tests for other substances in December 2017. Data on urine results and patients' characteristics were retrieved from the patients' records. RESULTS: Pregabalin was detected among 53 (17.7%) patients. The group had higher depressive symptoms severity score (21-HAM-D) (11.1⯱â¯8.4 vs. 8.3⯱â¯7.8, pâ¯=â¯0.03), a higher prevalence of sero-positive HIV (13.7% vs. 4.2%, pâ¯=â¯0.02), sero-positive hepatitis C (66.7% vs. 50.4%, pâ¯=â¯0.04), DSM-IV-TR Axis I psychiatric diagnosis (54.0% vs. 41.7%, pâ¯=â¯0.03), and positive urine for opiates (22.6% vs. 8.9%, pâ¯=â¯0.008), cannabis (39.6% vs. 4.0 pâ¯<â¯0.0005) benzodiazepine (BDZ) (77.4% vs. 18.2%, pâ¯<â¯0.0005) and oxycodone (11.3% vs. 0.4%, pâ¯<â¯0.0005). Logistic regression found pregabalin group as more likely to be urine positive to BDZ (ORâ¯=â¯12.8 95%CI 5.0-32.5) cannabis (ORâ¯=â¯22.7, 95%CI 6.3-81.6) and oxycodone (ORâ¯=â¯43.9, 95%CI 3.6-541.4), with higher 21-HAM-D scores (ORâ¯=â¯1.1, 95%CI 1.04-1.2) and hepatitis C sera-positive (ORâ¯=â¯4.1, 95% CI 1.5-11.4). Unexpectedly, 13.2% of the pregabalin group had take-home dose privileges, which are rewards to non-drug abusers. CONCLUSIONS: High prevalence of pregabalin misuse among both BDZ abusers and non-abusers and patients with depressive symptoms supports both the inclusion of routine monitoring for pregabalin and intervention in MMT population.
Subject(s)
Analgesics , Methadone , Opiate Substitution Treatment , Pregabalin , Prescription Drug Misuse/statistics & numerical data , Adult , Analgesics/therapeutic use , Cross-Sectional Studies , Female , Humans , Israel/epidemiology , Male , Methadone/therapeutic use , Middle Aged , Pregabalin/therapeutic use , Pregabalin/urine , Prevalence , Risk Factors , Substance Abuse Detection/statistics & numerical data , Substance-Related Disorders/psychology , Substance-Related Disorders/urineABSTRACT
Methadone maintenance treatment (MMT) patients are often under-nourished and overweight. The impact of a nutrition intervention program to improve knowledge about healthy food habits and losing weight was studied. Patients were screened for knowledge about nutrition and body mass index (BMI). Those with a low knowledge score or a BMI ≥26 (n=89) were randomly divided into either intervention (two lectures on healthy nutrition followed by weight monitoring over 6weeks), or controls (weighed at baseline, post-lectures and at study closure). The Yale Food Addiction Scale (YFAS), eating behavior rating, and nutrition knowledge questionnaires were used. Knowledge and food habit scores improved in the intervention group (28.4±4.3, 37.2±3.1, 32.5±3.9 pre-, post- and 6-weeks post-lectures, respectively), with no change in the controls (28.6±3.4, 28.2±4.9, 28.1±5.3, repeated measured p(time)=0.001, p(group)=0.001, p(interaction)=0.001); food habit (intervention: 35.0±7.0, 38.4±5.2, 37.5±5.3, controls: 34.0±6.9, 34.7±6.9, 34.6±7.4, p(time)=0.001, p(group)=0.04, p(interaction)=0.06). BMI scores however did not change and were similar in both groups (p=0.9). Of all patients, 10.1% met the criteria of food addiction according to the YFAS, 40.4% lost weight and 28% gained weight, with no group differences. There were more symptoms of food addiction among the patients who gained weight vs. those who lost weight (3.7±2.0 vs. 2.6±1.8, respectively, p=0.04). We concluded that although weight loss was not observed, intervention is recommended for improving knowledge about nutrition and for fostering healthy eating habits with the aim of reducing diet-related morbidity among all MMT patients. Longitudinal program combined with physical activity is needed to study if may lead to weight loss.
Subject(s)
Feeding Behavior , Health Knowledge, Attitudes, Practice , Nutritional Requirements , Opioid-Related Disorders/rehabilitation , Weight Loss , Adult , Female , Humans , Male , Methadone/therapeutic use , Opiate Substitution Treatment , Surveys and Questionnaires , Treatment OutcomeABSTRACT
BACKGROUND AND OBJECTIVES: Methadone maintenance treatment (MMT) is the gold standard for pregnant women with opioid use disorders. Still, low birth-weights were reported, in particular of mothers who became pregnant before admission to MMT. We studied whether an escalating incentive contingency-management approach may contribute to better newborn birth-weights. METHODS: A nationwide controlled randomized trial among all Israeli methadone/buprenorphine maintenance treatment (MBMT), newly or already in treatment pregnant women was performed. A modified contingency-management protocol with coupons of escalating value depending upon reduction of drug use, cigarette smoking, and alcohol consumption was compared to standard care arm. Drugs in urine, smoking (Fagerstrom score), alcohol use, and depression were monitored. RESULTS: Thirty-five women had 46 pregnancies. In their first pregnancy, 19 from the contingency-management and 16 from the standard care arms were studied. Contingency-management group as compared to the standard care arm included more newly admitted women (36.8% vs. 6.3%, p = .05), with benzodiazepine and cannabis onset at a younger age, and higher proportion of any drug abuse while pregnant (100% vs. 68.8%, p = .01). Fifteen of the contingency-management and 14 of the control arm gave birth (78.9% vs. 87.5%, p = .3) with similar proportions of normal (>2,500 g) birth-weight (71.4% vs. 61.5%, p = .8). CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Newborns' birth-weight was comparable among the two study arms indicating no contribution of the contingency-management approach. Small sample and baseline differences between arms might have influenced results. Intensive intervention should be evaluated on a larger scale of participants. (Am J Addict 2017;26:167-175).